NORMOCARB HF 25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORMOCARB HF 25 (NORMOCARB HF 25).
Calcium channel blocker; inhibits calcium ion influx across cardiac and smooth muscle cells, resulting in dilation of coronary and systemic arteries and negative chronotropic effects.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Primarily renal (80-90% as unchanged drug), with 10-20% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 5-7 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | 0.7-1.0 L/kg, indicating extensive distribution into tissues including myocardium. |
| Bioavailability | Oral: 60-80% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-15 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours. Duration may be prolonged in renal impairment. |
Oral: 25 mg once daily, titrate based on response; maximum 50 mg daily.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Start at 12.5 mg once daily; titrate cautiously based on renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORMOCARB HF 25 (NORMOCARB HF 25).
| Breastfeeding | Carbamazepine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.4–0.6. Estimated infant dose is about 2–5% of maternal weight-adjusted dose. While generally considered compatible with breastfeeding, monitor infant for sedation, poor sucking, and unusual drowsiness. Alternative anticonvulsants with lower excretion may be preferred in severe cases. |
| Teratogenic Risk | NORMOCARB HF 25 (carbamazepine, as per typical formulation) has been associated with increased risk of congenital malformations including neural tube defects (e.g., spina bifida), craniofacial defects, and developmental delay, particularly with first-trimester exposure. There is also a risk of fetal anticonvulsant syndrome. Risk of major malformations is approximately 2–3 times higher than baseline. In later trimesters, there is risk of neonatal hemorrhage, hepatic dysfunction, and withdrawal symptoms. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to diltiazem, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), cardiogenic shock, severe hypotension, atrial fibrillation with accessory bypass tract (e.g., WPW syndrome).
| Precautions | May precipitate heart failure; avoid in sick sinus syndrome or advanced heart block without pacemaker; caution in hypotension, hepatic impairment, and elderly patients. |
Loading safety data…
| Fetal Monitoring | Monitor maternal carbamazepine serum levels (therapeutic range 4–12 mcg/mL) due to increased clearance in pregnancy. Assess liver function tests, sodium levels, and complete blood count regularly. Perform detailed fetal ultrasound (including anatomical survey and neural tube defect screening) and fetal echocardiography. Supplement with folic acid (4–5 mg/day) preconception and through first trimester. Monitor for maternal toxicity signs (dizziness, ataxia, diplopia). |
| Fertility Effects | Carbamazepine may reduce fertility in women by inducing ovulation disorders, including polycystic ovary syndrome-like changes and decreased luteal phase progesterone. In men, it can reduce sperm motility and count via effects on Leydig cells and gonadotropins. These effects are generally reversible upon discontinuation. |